Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 75Neoplasm Metastasis 12Neoplasms 8Ovarian Neoplasms 6Endometrial Neoplasms 6Pancreatic Neoplasms 5Carcinoma, Renal Cell 5Sarcoma 4Neoplasms by Site 4Lymphoma, Non-Hodgkin 4Breast Diseases 4Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lymphoma 3Lung Neoplasms 3Liposarcoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Glioma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × palbociclib × 1 year × Clear all
NCT06570031 2026-06-05

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Completed
46 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06760637 2026-05-19

FourLight-3

Pfizer

Phase 3 Active not recruiting
1,035 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡